Literature DB >> 9636649

Expression of endoglin mRNA and protein in human vascular smooth muscle cells.

P J Adam1, G J Clesham, P L Weissberg.   

Abstract

Endoglin, the gene linked to the autosomal dominant vascular disorder hereditary hemorrhagic telangiectasia type 1 (HHT1), encodes a 95-kDa membrane-bound proteoglycan which binds TGF beta 1 and regulates signaling via the type I and II TGF beta receptors on the surface of vascular endothelial cells. Using reverse-transcription polymerase chain reaction (RT-PCR) and Northern blot analysis we have shown that endoglin mRNA is expressed in both cultured human VSMCs and VSMCs freshly isolated from human aortas. Northern blot analysis was also used to demonstrate that endoglin expression decreased in serum-stimulated cultured human VSMCs but could be maintained by exogenous TGF beta 1. Endoglin protein expression in human VSMCs was shown by immunocytochemistry. These data, the first describing the existence of endoglin in VSMCs, suggest that through regulating TGF beta 1 signaling endoglin may mediate the effects of TGF beta 1 on VSMC behavior in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9636649     DOI: 10.1006/bbrc.1998.8734

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms.

Authors:  C L Shovlin; M Letarte
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Physiology of angiogenesis.

Authors:  H Kurz
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

3.  Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Juan P Kusanovic; Zeynep A Savasan; Sun Kwon Kim; Shali Mazaki-Tovi; Edi Vaisbuch; Giovanna Ogge; Ichchha Madan; Zhong Dong; Lami Yeo; Pooja Mittal; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2010-08

4.  Temporal changes in renal endoglin and TGF-beta1 expression following ureteral obstruction in rats.

Authors:  M Prieto; A B Rodríguez-Peña; A Düwel; J V Rivas; N Docherty; F Pérez-Barriocanal; M Arévalo; C P H Vary; C Bernabeu; J M López-Novoa; N Eleno
Journal:  J Physiol Biochem       Date:  2005-09       Impact factor: 4.158

5.  Endoglin (CD105) up-regulation in pulmonary microvasculature of ventilated preterm infants.

Authors:  Monique E De Paepe; Chintan Patel; Amy Tsai; Sravanthi Gundavarapu; Quanfu Mao
Journal:  Am J Respir Crit Care Med       Date:  2008-04-17       Impact factor: 21.405

Review 6.  Novel biochemical pathways of endoglin in vascular cell physiology.

Authors:  Carmelo Bernabeu; Barbara A Conley; Calvin P H Vary
Journal:  J Cell Biochem       Date:  2007-12-15       Impact factor: 4.429

7.  Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK1 mutations.

Authors:  J Berg; M Porteous; D Reinhardt; C Gallione; S Holloway; T Umasunthar; A Lux; W McKinnon; D Marchuk; A Guttmacher
Journal:  J Med Genet       Date:  2003-08       Impact factor: 6.318

8.  Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients.

Authors:  Ana M Blázquez-Medela; Luis García-Ortiz; Manuel A Gómez-Marcos; José I Recio-Rodríguez; Angel Sánchez-Rodríguez; José M López-Novoa; Carlos Martínez-Salgado
Journal:  BMC Med       Date:  2010-12-20       Impact factor: 8.775

9.  Shear induced collateral artery growth modulated by endoglin but not by ALK1.

Authors:  Leonard Seghers; Margreet R de Vries; Evangelia Pardali; Imo E Hoefer; Beerend P Hierck; Peter ten Dijke; Marie Jose Goumans; Paul H A Quax
Journal:  J Cell Mol Med       Date:  2012-10       Impact factor: 5.310

Review 10.  Endoglin: a critical mediator of cardiovascular health.

Authors:  Navin K Kapur; Kevin J Morine; Michelle Letarte
Journal:  Vasc Health Risk Manag       Date:  2013-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.